How to Invest in Iteos Therapeutics?
Iteos Therapeutics Investing Guide | ITOS |
- Research Iteos Therapeutics' stock before investing in Iteos Therapeutics. It's a good idea to research the company and its stock by analyzing its financial statements, reading news articles, and studying its historical performance, including its growth strategy, change in net worth, competition, and potential risks.
- Choose a brokerage firm to buy shares of Iteos Therapeutics. We recommend well-established brokerages such as Charles Schwab, Fidelity, TD Ameritrade, and Robinhood, but in many ways, it will depend on your individual needs, preferences, and investment goals.
- Open an account at one of the brokerages you have selected. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account. You will need to deposit funds into your brokerage account to purchase Iteos Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order. Once you have located Iteos Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock.
It's important to note that investing in stocks such as Iteos Therapeutics carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions regarding Iteos Stock. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to invest safely in Iteos Therapeutics.
Research Iteos Therapeutics Stock
Researching Iteos Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E).
About 99.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iteos Therapeutics recorded a loss per share of 3.14. The entity had not issued any dividends in recent years. Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people. To learn more about Iteos Therapeutics call Michel Detheux at 339 217 0161 or check out https://www.iteostherapeutics.com. Other things to consider when investing in Iteos
Another important aspect of Iteos Therapeutics' research is to evaluate the company's potential for future growth. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Iteos Therapeutics' research are outlined below:
| Iteos Therapeutics generated a negative expected return over the last 90 days | |
| Iteos Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 12.6 M. Net Loss for the year was (112.64 M) with profit before overhead, payroll, taxes, and interest of 267.63 M. | |
| Iteos Therapeutics currently holds about 791.86 M in cash with (103.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Iteos Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: iTeos Therapeutics CFO Matthew Gall acquires 38,635 in common stock |
Check Iteos Therapeutics' earnings reports
Iteos Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Iteos Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Iteos Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Use historical earnings surprises to time your Iteos Therapeutics position
Earnings surprises can significantly impact Iteos Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Iteos Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | 0.1 | 0.03 | -0.07 | 70 | ||
2021-05-13 | 2021-03-31 | -0.48 | -0.39 | 0.09 | 18 | ||
2020-11-12 | 2020-09-30 | -0.36 | -0.48 | -0.12 | 33 | ||
2024-11-05 | 2024-09-30 | -0.89 | -1.0515 | -0.1615 | 18 | ||
2024-03-06 | 2023-12-31 | -1.03 | -0.85 | 0.18 | 17 | ||
2024-05-10 | 2024-03-31 | -1.26 | -1.07 | 0.19 | 15 | ||
2023-03-15 | 2022-12-31 | 0.33 | 0.56 | 0.23 | 69 | ||
2023-11-07 | 2023-09-30 | -1.2 | -0.9 | 0.3 | 25 |
Know Iteos Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Iteos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iteos Therapeutics backward and forwards among themselves. Iteos Therapeutics' institutional investor refers to the entity that pools money to purchase Iteos Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 963.9 K | Goldman Sachs Group Inc | 2024-06-30 | 732.3 K | Deerfield Management Co | 2024-06-30 | 723 K | Citadel Advisors Llc | 2024-06-30 | 697.3 K | Geode Capital Management, Llc | 2024-06-30 | 620.3 K | Renaissance Technologies Corp | 2024-09-30 | 536.4 K | Candriam Luxembourg S.c.a. | 2024-06-30 | 509.3 K | Jpmorgan Chase & Co | 2024-06-30 | 462 K | Nuveen Asset Management, Llc | 2024-06-30 | 358.2 K | Blackrock Inc | 2024-06-30 | 3.7 M | Ra Capital Management, Llc | 2024-06-30 | 3.5 M |
Follow Iteos Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 297.02 M.Market Cap |
|
Evaluate Iteos Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.20) | (0.21) |
Determining Iteos Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to assess its ability to generate profits. Also, when deciding whether to invest in Iteos Therapeutics, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Iteos Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Iteos Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Iteos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Iteos Therapeutics. Check Iteos Therapeutics' Beneish M Score to see the likelihood of Iteos Therapeutics' management manipulating its earnings.
Evaluate Iteos Therapeutics' management efficiency
Iteos Therapeutics has return on total asset (ROA) of (0.1304) % which means that it has lost $0.1304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1972) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2024. Return On Capital Employed is likely to drop to -0.25 in 2024. At this time, Iteos Therapeutics' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 122.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 3.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.08 | 8.28 | |
| Tangible Book Value Per Share | 16.08 | 8.28 | |
| Enterprise Value Over EBITDA | (0.97) | (1.02) | |
| Price Book Value Ratio | 0.68 | 0.65 | |
| Enterprise Value Multiple | (0.97) | (1.02) | |
| Price Fair Value | 0.68 | 0.65 | |
| Enterprise Value | 372.8 M | 454.1 M |
The management team at Iteos Therapeutics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 1.39 |
Basic technical analysis of Iteos Stock
As of the 23rd of November, Iteos Therapeutics retains the Standard Deviation of 4.4, risk adjusted performance of (0.17), and Market Risk Adjusted Performance of (0.77). Iteos Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Iteos Therapeutics mean deviation and maximum drawdown to decide if Iteos Therapeutics is priced fairly, providing market reflects its last-minute price of 8.32 per share. Given that Iteos Therapeutics has information ratio of (0.26), we strongly advise you to confirm Iteos Therapeutics's regular market performance to make sure the company can sustain itself at a future point.Check Iteos Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iteos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iteos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iteos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Evaluate Iteos Therapeutics' Outstanding Corporate Bonds
Iteos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Iteos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Iteos bonds can be classified according to their maturity, which is the date when Iteos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| ITC HLDGS P Corp BondUS465685AH81 | View | |
| ITC HLDGS P Corp BondUS465685AK11 | View | |
| US465685AQ80 Corp BondUS465685AQ80 | View | |
| ITC HLDGS P Corp BondUS465685AP08 | View | |
| ITC 495 22 SEP 27 Corp BondUS465685AR63 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Iteos Therapeutics' technical indicators
Using predictive indicators to make investment decisions involves analyzing Iteos Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | (0.77) | |||
| Mean Deviation | 2.64 | |||
| Coefficient Of Variation | (420.07) | |||
| Standard Deviation | 4.4 | |||
| Variance | 19.39 | |||
| Information Ratio | (0.26) | |||
| Jensen Alpha | (1.19) | |||
| Total Risk Alpha | (1.63) | |||
| Treynor Ratio | (0.78) | |||
| Maximum Drawdown | 33.24 | |||
| Value At Risk | (4.52) | |||
| Potential Upside | 4.26 | |||
| Skewness | (3.08) | |||
| Kurtosis | 19.95 |
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | (0.77) | |||
| Mean Deviation | 2.64 | |||
| Coefficient Of Variation | (420.07) | |||
| Standard Deviation | 4.4 | |||
| Variance | 19.39 | |||
| Information Ratio | (0.26) | |||
| Jensen Alpha | (1.19) | |||
| Total Risk Alpha | (1.63) | |||
| Treynor Ratio | (0.78) | |||
| Maximum Drawdown | 33.24 | |||
| Value At Risk | (4.52) | |||
| Potential Upside | 4.26 | |||
| Skewness | (3.08) | |||
| Kurtosis | 19.95 |
Consider Iteos Therapeutics' intraday indicators
Iteos Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Iteos Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Iteos Therapeutics Corporate Filings
13A | 21st of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Choose a brokerage platform to buy Iteos Therapeutics' shares
In investing, finding the right broker is a crucial step for anyone looking to embark on a journey into the stock market. It all begins with a thorough comparison of costs and fees, as low-cost or commission-free brokers can significantly impact an investor's returns. However, the cheapest option is not always the best choice. The adventure continues with exploring various trading platforms, seeking one that is user-friendly, reliable, and functional. The ideal platform will provide the necessary research, analysis, and investment monitoring tools. As the quest goes on, it's essential to consider the different account types brokers offer, such as individual, joint, and retirement accounts. In addition, for those interested in trading on margin, brokers offering margin accounts should also be considered. The journey leads to the discovery of brokers that provide a wide range of investment options, including stocks, bonds, ETFs, and mutual funds. This diversity allows investors to build well-rounded portfolios that suit their needs and goals. Customer service is another crucial factor in this decision-making process. The perfect broker would have a responsive, knowledgeable, and available customer support team ready to assist with various issues or investment decisions. Aspiring investors should seek brokers with quality research, market analysis, and educational resources. These tools are essential for making informed decisions and improving investment knowledge. It's also vital to ensure that the broker is regulated by an appropriate regulatory body and has robust security measures to protect personal and financial information. Additionally, account minimums and funding options should be taken into consideration. A broker with flexible account minimums and various funding options, such as wire transfers, ACH transfers, or check deposits, will cater to different investor needs. A seamless mobile and web experience is a must in today's fast-paced world. The ideal broker will allow investors to manage their investments easily on the go. Finally, it is essential to consider various brokers' reviews and conduct reputation analysis. By reading online assessments and seeking recommendations, valuable insights into each broker's reputation can be gathered. After a thorough investigation, you can find a broker that checks all the boxes and aligns with their preferences and requirements regarding taking a position in Iteos Therapeutics.
Open brokerage account to buy Iteos Stock
Once you've selected a broker, visit their website or a local branch to initiate the account-opening process. Most brokers offer online account opening, which is typically faster and more convenient. When you begin the process, you'll need to select the type of account you want to open. This may include individual, joint, or retirement accounts. Some brokers may also offer margin accounts, which allow you to trade on margin. Next, you'll need to complete the application form. Whether you're filling out an online or paper application, you'll need to provide personal information, such as your name, address, Social Security Number or other tax identification number, date of birth, and employment information. You may also be asked about your investment experience, financial situation, and goals. After completing the application form, review it carefully for accuracy and submit it to the broker. Some brokers may require you to provide additional documentation, such as a copy of your driver's license or passport, for identity verification. Once your application is submitted, the broker will review it and may run a background check or verify your credit history. You'll receive an email or notification with your new brokerage account details if your application is approved.
Fund your account to invest in Iteos Stock
Once your account is open, you can fund it by linking your bank account to your brokerage account. To do this, log in to your brokerage account and look for an option to add or link a bank account. You will need to provide your bank account number and the routing number for your bank. This information can be found on your checks or by contacting your bank. After linking your bank account, you can initiate a transfer of funds from your bank account to your brokerage account. This process may vary depending on the brokerage, but generally, you will need to navigate to the funding or deposit section of the brokerage website or app. From there, you can choose the linked bank account and enter the amount you wish to transfer. Keep in mind that there may be limits on the amount you can transfer in a single transaction, and the transfer may take several business days to complete. Some brokerages also offer other funding options, such as wire transfers, mailing a check, or transferring assets from another brokerage. If you prefer to use one of these methods, check with your brokerage firm for specific instructions. Once the funds are in your brokerage account, you can use them to purchase investments such as stocks, bonds, mutual funds, or other financial instruments.
Place your Iteos Stock order
Placing an Iteos Therapeutics purchase order involves providing instructions to your selected brokerage firm to aquare shares of Iteos Therapeutics on your behalf. First, your will need to access your brokerage account through their website or mobile app using your login credentials. Make sure you have sufficient funds in your account to cover the cost of the stock purchase, including any applicable fees or commissions. Once you are logged in, locate the trading platform or order entry section within the brokerage interface. It may be labeled as "Trade," "Order Entry," or something similar. Next, you will need to provide the necessary information to place your stock order. This typically includes: .
After entering the necessary information, review your order carefully to ensure it reflects your intentions accurately. When you are ready, submit your order by clicking the "Submit," "Place Order," or equivalent button. Your brokerage firm will then execute your order according to your instructions, subject to market conditions and the availability of shares. Keep in mind that market orders may be executed immediately, while limit orders, stop orders, and stop-limit orders will only be executed if the specified conditions are met. Finally, monitor your order status and confirm its execution. You can usually find this information in the "Order History" or "Order Status" section of your brokerage account.
| Ticker | Enter the ticker symbol, which is the unique series of letters representing the stock, e.g., ITOS for Iteos Therapeutics | |
| Type | Choose the type of order you want to place. The most common order types are market orders, limit orders, stop orders, and stop-limit orders. Each order type has its own advantages and drawbacks, so be sure to research and understand them before placing your order. | |
| Quantity | Specify the number of shares you want to buy or sell | |
| Duration | Indicate the duration for which your order will be active. You can choose from options like "Day" (valid only for the current trading day) or "Good 'til Canceled" (valid until you manually cancel the order) |
Monitor your Iteos Stock position
Monitoring your stock positions with your brokerage involves regularly checking the status and performance of your investments. Here's how you can monitor your stock positions using your brokerage account: First, access your account by signing in to your brokerage firm's website or mobile app using your login credentials. Once you're logged in, look for the section that displays your account information and portfolio holdings. This section may be labeled as "Portfolio," "Positions," "Holdings," or something similar. In this section, you'll generally find a list of the stocks and other investments that you own, along with relevant details such as the number of shares, the current market value, and the percentage change in value since the last trading day's close. You might also see the total cost of your investment, your current profit or loss, and the percentage gain or loss. Many brokerages also provide tools and features that allow you to analyze and track your stock positions more effectively. These may include:
As you continue to monitor your Iteos Stock position, remember that in order to be an effective trader, it is critical to understand your entire portfolio's sensitivity to market volatility and how your single Iteos Therapeutics position affects your overall exposure to market risk. One of the techniques to manage your overall risk is pair trading, a market-neutral trading strategy enabling traders to profit from virtually any market condition, whether it is experiencing an uptrend or downtrend movement.
| Performance Charts | These charts visually represent the historical price movement of your stocks over different time frames. You can use them to assess the trends and volatility of your investments. | |
| Stock Alerts | You can set up custom alerts to receive notifications when a stock reaches a certain price, percentage change, or other criteria. This can help you stay informed about significant market movements affecting your investments. | |
| Watchlists | Create watchlists to track the performance of stocks you are interested in but have not yet purchased. This can help you identify potential opportunities or risks. | |
| Research Tools | Brokerages often provide access to research tools, such as stock screeners, analyst reports, and financial statements, to help you make more informed investment decisions. |
Moving together with Iteos Stock
| 0.91 | VALN | Valneva SE ADR | PairCorr |
| 0.72 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.7 | IPSC | Century Therapeutics | PairCorr |
| 0.66 | MTEM | Molecular Templates | PairCorr |
Moving against Iteos Stock
It's a good idea to monitor your stock positions regularly to ensure that your investments align with your financial goals and risk tolerance. Keep in mind that the stock market can be volatile, and it's essential to maintain a long-term perspective when evaluating your portfolio's performance.Follow Iteos Stock across various news and media outlets
Far too much social signal, news, headlines, and media speculation about Iteos Therapeutics that are available to investors today. That information is available publicly through Iteos media outlets and privately through word of mouth or via Iteos internal channels. However, regardless of the origin, that massive amount of Iteos data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Iteos Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iteos Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iteos Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iteos Therapeutics alpha.